<?xml version="1.0" encoding="UTF-8"?>
<p>Patients ≥18 years old were registered using an Interactive Registration System. The study was designed specifically for older (≥55 years) patients; however, up to 10 patients aged &lt;55 years were permitted to enter the study for exploratory purposes. After these 10 patients were enrolled, enrollment was restricted to patients aged ≥55 years. Patients had newly diagnosed or previously untreated AML (
 <italic>de novo</italic> AML, AML evolving from an antecedent hematologic disease or MDS, or AML secondary to previous cytotoxic or radiation therapy) or refractory anemia with excess blast 2 high‐risk MDS, according to the World Health Organization 2008 classification.
</p>
